Creative Medical Technology Holdings Files Patent on Anti-aging Technology Using AmnioStem Stem Cells
PR Newswire
PHOENIX, May 8, 2018
PHOENIX, May 8, 2018 /PRNewswire/ -- Creative Medical Technology Holdings
announced today filing of patent application number 62663912 covering the use
of its AmnioStem^TM stem cells as a means of reducing/reversing natural
aging.
Previous studies by the Company have demonstrated that AmnioStem^TM cells
secrete factors that are capable of rejuvenating aged cells. By encapsulating
the cells outside of the body, so that the cells are in contact with the
patient's circulation, the cells are permitted to secrete factors that may
reduce aging, without having to inject the cells in the patient.
The concept of using cells that are growing outside of the body as a means of
modifying physiological activities has previously been performed and appears
feasible. Specifically, similar approaches to mixing patient blood with cells
outside of the body have previously been attempted in the area of liver
failure. A clinical trial demonstrated feasibility of using cell culture of
hepatocytes to act as a "liver assist device". These devices are currently in
Phase 3 of clinical trials^1,^2.
The filed patent describes a similar approach to those used in liver failure,
with the exception that instead of using hepatocytes outside of the body, the
device uses AmnioStem^TM amniotic fluid derived stem cells.
"Previous studies from Stanford University^3 and Harvard University^4 have
shown that if the circulation of an aged mouse is connected to the circulation
of a young mouse, various factors secreted by young mice induce an
anti-aging/rejuvenating effects on organs/tissues of aged mice. Through this
patent, we are aiming to recapitulate this effect, in an ethical and
technically feasible manner." Said Dr. Thomas Ichim, the Company's Chief
Scientific Officer. "What is stunning about the AmnioStem^TM stem cell, which
was licensed by the Company from the University of California San Diego, is
that it possesses many regenerative features but is collected from
non-controversial sources."
The AmnioStem^TM stem cell is derived from amniotic fluid during the process
of amniocentesis. Amniotic fluid is typically considered medical waste.
Scientists at University of California San Diego have developed means of
extracting and growing stem cells from the amniotic fluid. These stem cells
have been published to be capable of treating animal models of numerous
diseases including stroke^5, heart attack^6, liver failure^7, colitis^8,
diabetes^9, emphysema^10, and kidney injury^11. An important activity of
amniotic fluid stem cells is that cells derived from one person can be used to
treat other people, making them "universal donor" stem cells.
"The concept of using young blood to stimulate regeneration in aged
individuals is attracting much attention in the area of regenerative
medicine. I am enthusiastic about the approach being developed by Creative
Medical Technology Holdings, which overcomes some of the important roadblocks
that prevent implementation of this novel and promising approach," said Amit
Patel, MD, MS, Chief of Cardiothoracic Surgery University of Miami and
coinventor of the patent.
"At Creative Medical Technology Holdings we are committed to advancing
regenerative medicine to various areas of human suffering. In contrast to
other conditions, aging will occur in everyone," said Timothy Warbington,
President and CEO of Creative Medical Technology Holdings. "While the field of
anti-aging medicine is filled with various false hopes and hype, we are
attempting to address this problem cautiously and methodologically through
testing our technology for safety and efficacy.
"Our goal is to continue to internally develop and patent technology in the
regenerative medicine space and to broaden our patent portfolio for future
commercialization by the company and/or with other life science companies with
complementary technology."
PR Newswire
PHOENIX, May 8, 2018
PHOENIX, May 8, 2018 /PRNewswire/ -- Creative Medical Technology Holdings
announced today filing of patent application number 62663912 covering the use
of its AmnioStem^TM stem cells as a means of reducing/reversing natural
aging.
Previous studies by the Company have demonstrated that AmnioStem^TM cells
secrete factors that are capable of rejuvenating aged cells. By encapsulating
the cells outside of the body, so that the cells are in contact with the
patient's circulation, the cells are permitted to secrete factors that may
reduce aging, without having to inject the cells in the patient.
The concept of using cells that are growing outside of the body as a means of
modifying physiological activities has previously been performed and appears
feasible. Specifically, similar approaches to mixing patient blood with cells
outside of the body have previously been attempted in the area of liver
failure. A clinical trial demonstrated feasibility of using cell culture of
hepatocytes to act as a "liver assist device". These devices are currently in
Phase 3 of clinical trials^1,^2.
The filed patent describes a similar approach to those used in liver failure,
with the exception that instead of using hepatocytes outside of the body, the
device uses AmnioStem^TM amniotic fluid derived stem cells.
"Previous studies from Stanford University^3 and Harvard University^4 have
shown that if the circulation of an aged mouse is connected to the circulation
of a young mouse, various factors secreted by young mice induce an
anti-aging/rejuvenating effects on organs/tissues of aged mice. Through this
patent, we are aiming to recapitulate this effect, in an ethical and
technically feasible manner." Said Dr. Thomas Ichim, the Company's Chief
Scientific Officer. "What is stunning about the AmnioStem^TM stem cell, which
was licensed by the Company from the University of California San Diego, is
that it possesses many regenerative features but is collected from
non-controversial sources."
The AmnioStem^TM stem cell is derived from amniotic fluid during the process
of amniocentesis. Amniotic fluid is typically considered medical waste.
Scientists at University of California San Diego have developed means of
extracting and growing stem cells from the amniotic fluid. These stem cells
have been published to be capable of treating animal models of numerous
diseases including stroke^5, heart attack^6, liver failure^7, colitis^8,
diabetes^9, emphysema^10, and kidney injury^11. An important activity of
amniotic fluid stem cells is that cells derived from one person can be used to
treat other people, making them "universal donor" stem cells.
"The concept of using young blood to stimulate regeneration in aged
individuals is attracting much attention in the area of regenerative
medicine. I am enthusiastic about the approach being developed by Creative
Medical Technology Holdings, which overcomes some of the important roadblocks
that prevent implementation of this novel and promising approach," said Amit
Patel, MD, MS, Chief of Cardiothoracic Surgery University of Miami and
coinventor of the patent.
"At Creative Medical Technology Holdings we are committed to advancing
regenerative medicine to various areas of human suffering. In contrast to
other conditions, aging will occur in everyone," said Timothy Warbington,
President and CEO of Creative Medical Technology Holdings. "While the field of
anti-aging medicine is filled with various false hopes and hype, we are
attempting to address this problem cautiously and methodologically through
testing our technology for safety and efficacy.
"Our goal is to continue to internally develop and patent technology in the
regenerative medicine space and to broaden our patent portfolio for future
commercialization by the company and/or with other life science companies with
complementary technology."
Louis Pasteur -- chance favours only the prepared mind.
Lecture, University of Lille (7 December 1854)
Lecture, University of Lille (7 December 1854)
